In the immunohistochemistry (IHC) analysis of xenograft tumor sections, the expression of Ki-67 as the proliferation marker was lower in the combination treatment group than in the sunitinib or Rh2 treatment group (Fig. 1F). This evidence concerns the gene RHAG and neoplasm.